Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer

Immunotherapy

Volumn 2, Issue 4, 2010, Pages 551-560

  Alexandroff, Anton B ^a   Nicholson, Steve ^a   Patel, Poulam M ^b   Jackson, Andrew M ^b  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

bacillus CalmetteGuerin; bladder cancer; CD40; imiquimod; regulatory T cell; T helper 17; vaccine

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; DOXORUBICIN; EPIRUBICIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INACTIVATED VACCINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; LIVE VACCINE; MITOMYCIN C; OFLOXACIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADD ON THERAPY; ANTIBIOTIC PROPHYLAXIS; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER THERAPY; CLINICAL PRACTICE; CYSTECTOMY; CYSTITIS; CYTOKINE PRODUCTION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOTHERAPY; LOW DRUG DOSE; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MEDICAL SOCIETY; MYCOBACTERIUM; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SURVIVAL RATE; SURVIVAL TIME;

BCG VACCINE; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; URINARY BLADDER NEOPLASMS;

EID: 77954980492     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.32     Document Type: Review

References (109)

1. Alexandroff AB, James K: Immunotherapy of bladder cancer. In: Cancer Vaccines and Immunotherapy. Stern PL, Berverley P, Carroll MW (Eds).Cambridge University Press, UK, 19-46 (2000).
2. Alexandroff AB, Jackson AM, ODonnell MA, James K: BCG immunotherapy of bladder cancer: 20 years on. Lancet 353(9165), 1689-1694 (1999).
3. Centanni E, Rezzesi F: Studio sperimentale sullantagonismo fra tuberculosi e carno. Rif. Med. 42, 195-200 (1926).
4. Holmgren I: La tuberculine di le BCG chez les concereux. Schweiz. Med. Wochenschr. 65, 1203-1206 (1935).
5. Mathe G, Amiel JL, Schwarzenberg L et al.: Active immunotherapy for acute lymphoblastic leukaemia. Lancet 1(7597), 697-699 (1969).
6. Morales A, Eidinger D, Bruce AW: Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol. 116(2), 180-183 (1976).
7. Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM: bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J. Urol. 124(1), 38-40 (1980).
8. Lamm DL, Blumenstein BA, Crawford D et al.: Randomised intergroup comparison of Bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder. Urol. Oncol. 1, 119-126 (1995).
9. Hussain MH, Wood DP, Bajorin DF et al.: Bladder cancer: narrowing the gap between evidence and practice. J. Clin. Oncol. 27(34), 5680-5684 (2009).
10. Shelley MD, Mason MD, Kynaston H: Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treat. Rev. 36(3), 195-205 (2010).
11. Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M: Intravesical bacillus Calmette-Guerin in Ta and T1 bladder cancer. Cochrane Database Syst. Rev. (4), CD001986 (2000).
12. Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, Mason M: Intravesical Bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst. Rev. (3), CD003231 (2003).
13. Malmstrom PU, Sylvester RJ, Crawford DE et al.: An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette- Guerin for non-muscle-invasive bladder cancer. Eur. Urol. 56(2), 247-256 (2009).
14. Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K: Bacillus Calmette- Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J. Urol. 174(1), 86-91 (2005).
15. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 54(2), 303-314 (2008).
16. Joudi FN, Smith BJ, ODonnell MA: Final results from a national multicenter Phase II trial of combination bacillus Calmette- Guerin plus interferon a-2B for reducing recurrence of superficial bladder cancer. Urol. Oncol. 24(4), 344-348 (2006).
17. Gallagher BL, Joudi FN, Maymi JL, ODonnell MA: Impact of previous bacille Calmette-Guerin failure pattern on subsequent response to bacille Calmette- Guerin plus interferon intravesical therapy. Urology 71(2), 297-301 (2008)
18. Skolarus TA, Lee EW, Virgo KS et al.: Intravesical bacille Calmette-Guerin therapy for non-muscle-invasive bladder cancer: effects of concurrent statin therapy. J. Am. Coll. Surg. 209(2), 248-253 (2009).
19. Berglund RK, Savage CJ, Vora KC, Kurta JM, Cronin AM: An analysis of the effect of statin use on the efficacy of bacillus Calmette- Guerin treatment for transitional cell carcinoma of the bladder. J. Urol. 180(4), 1297-1300 (2008).
20. Kresowik TP , Griffith TS: Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder. Immunotherapy. 1(2), 281-288 (2009).
21. Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L, Rischmann P: The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J. Urol. 176(3), 935-939 (2006).
22. Sun HY, Singh N: Should intravesical bacillus Calmette-Guerin be employed in transplant recipients with bladder carcinoma? Transpl. Infect. Dis. DOI: 10.1111/j.1399-3062.2010. 00506.x (2010) (Epub ahead of print).
23. Becich MJ, Carroll S, Ratliff TL: Internalization of bacille Calmette-Guerin by bladder tumor cells. J. Urol. 145(6), 1316-1324 (1991).
24. Luo Y, Chen X, ODonnell MA: Mycobacterium bovis bacillus Calmette- Guerin (BCG) induces human CC-and CXC-chemokines in vitro and in vivo. Clin. Exp. Immunol. 147(2), 370-378 (2007).
25. Alexandrov AV, Jackson AM, Rumyantsev AG: Mechanisms of modulation of intercellular adhesion molecules ICAMs. Immunologia (1), 4-13 (1997).
26. Esuvaranathan K, Alexandroff AB, McIntyre M et al.: Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. J. Urol. 154(2 Pt 1), 572-575 (1995).
27. Prescott S, Jackson AM, Hawkyard SJ, Alexandroff AB, James K: Mechanisms of action of intravesical bacille Calmette- Guerin: local immune mechanisms. Clin. Infect. Dis. 31(Suppl. 3), S91-S93 (2000).
28. Zhang Y, Khoo HE, Esuvaranathan K: Effects of bacillus Calmette-Guerin and interferon a-2B on cytokine production in human bladder cancer cell lines. J. Urol. 161(3), 977-983 (1999).
29. Sander B, Damm O, Gustafsson B, Andersson U, Hakansson L: Localization of IL-1, IL-2, IL-4, IL-8 and TNF in superficial bladder tumors treated with intravesical bacillus Calmette-Guerin. J. Urol. 156(2 Pt 1), 536-541 (1996). (Pubitemid 126445375)
30. Alexandroff AB, Jackson AM, Skibinska A et al.: Bladder cancer cells do not express co-stimulatory molecules B7-1, B7-2 and B7-3: evidence for the existence of an additional ligand for LFA-1. Int. J. Oncol. 8(6), 1273-1282 (1996).
31. Ikeda N, Toida I, Iwasaki A, Kawai K, Akaza H: Surface antigen expression on bladder tumor cells induced by bacillus Calmette-Guerin (BCG): a role of BCG internalization into tumor cells. Int. J. Urol. 9(1), 29-35 (2002).
32. + T-cells. Cancer Res. 52(15), 4286-4290 (1992).
33. See WA, Zhang G, Chen F, Cao Y, Langenstroer P, Sandlow J: Bacille-Calmette Guerin induces caspase-independent cell death in urothelial carcinoma cells together with release of the necrosis-associated chemokine high molecular group box protein 1. BJU. Int. 103(12), 1714-1720 (2009).
34. Jackson AM, Alexandroff AB, Fleming D, Prescott S, Chisholm GD, James K: Bacillus-Calmette-Guerin (BCG) organisms directly alter the growth of bladder-tumor cells. Int. J. Oncol. 5(3), 697-703 (1994).
35. Higuchi T, Shimizu M, Owaki A et al.: A possible mechanism of intravesical BCG therapy for human bladder carcinoma: involvement of innate effector cells for the inhibition of tumor growth. Cancer Immunol. Immunother. 58(8), 1245-1255 (2009).
36. Demangel C , Britton WJ: Interaction of dendritic cells with mycobacteria: where the action starts. Immunol. Cell Biol. 78(4), 318-324 (2000).
37. Ramoner R, Rieser C, Herold M et al.: Activation of human dendritic cells by bacillus Calmette-Guerin. J. Urol. 159(5), 1488-1492 (1998).
38. Cheadle EJ, Selby PJ, Jackson AM: Mycobacterium bovis bacillus Calmette- Guerin-infected dendritic cells potently activate autologous T cells via a B7 and interleukin-12-dependent mechanism. Immunology 108(1), 79-88 (2003).
39. Naoe M, Ogawa Y, Takeshita K et al.: Bacillus Calmette-Guerin-pulsed dendritic cells stimulate natural killer T cells and gdT cells. Int. J. Urol. 14(6), 532-538 (2007).
40. Ratliff TL, Ritchey JK, Yuan JJ, Andriole GL, Catalona WJ: T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J. Urol. 150(3), 1018-1023 (1993).
41. Simons MP, ODonnell MA, Griffith TS: Role of neutrophils in BCG immunotherapy for bladder cancer. Urol. Oncol. 26(4), 341-345 (2008).
42. Pryor K, Goddard J, Goldstein D et al.: Bacillus Calmette-Guerin (BCG) enhances monocyte-and lymphocyte-mediated bladder tumour cell killing. Br. J. Cancer 71(4), 801-807 (1995).
43. Luo Y, Yamada H, Evanoff DP, Chen X: Role of Th1-stimulating cytokines in bacillus Calmette-Guerin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells. Clin. Exp. Immunol. 146(1), 181-188 (2006).
44. Ayari C, LaRue H, Hovington H et al.: Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guerin immunotherapy. Eur. Urol. 55(6), 1386-1395 (2009).
45. Jackson AM, Alexandroff AB, Kelly RW et al.: Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after Bacillus Calmette-Guerin (BCG) immunotherapy. Clin. Exp. Immunol. 99(3), 369-375 (1995).
46. Eto M, Koga H, Noma H, Yamaguchi A, Yoshikai Y, Naito S: Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus Calmette-Guerin for superficial bladder tumors. Urol. Int. 75(2), 114-118 (2005).
47. Saint F, Kurth N, Maille P et al.: Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guerin response of superficial bladder cancer during induction course and maintenance therapy. Int. J. Cancer 107(3), 434-440 (2003).
48. Watanabe E, Matsuyama H, Matsuda K et al.: Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette- Guerin immunotherapy for carcinoma in situ of the bladder. Cancer Immunol. Immunother. 52(8), 481-486 (2003).
49. Magno C, Melloni D, Gali A et al.: The anti-tumor activity of bacillus Calmette-Guerin in bladder cancer is associated with an increase in the circulating level of interleukin-2. Immunol. Lett. 81(3), 235-238 (2002).
50. Sanchez-Carbayo M, Urrutia M, Romani R, Herrero M, Gonzalez de Buitrago JM, Navajo JA: Serial urinary IL-2, IL-6, IL-8, TNFα, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG. Anticancer Res. 21(4B), 3041-3047 (2001).
51. Kaempfer R, Gerez L, Farbstein H et al.: Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J. Clin. Oncol. 14(6), 1778-1786 (1996).
52. Alexandroff AB, Jackson AM, Skibinska A, James K: Production of IL-5, a classical T(h)2 cytokine, following bacillus Calmette Guerin immunotherapy of bladder cancer. Int. J. Oncol. 9(1), 179-182 (1996).
53. Peuchmaur M, Vieillefond A, Benoit G, Jardin A: [Analysis of lymphocyte subpopulations of the bladder following endovesical immunotherapy using BCG]. Ann. Urol. (Paris) 23(3), 246-250 (1989).
54. Dethlefsen SM, Matsuura N, Zetter BR: Mast cell accumulation at sites of murine tumor implantation: implications for angiogenesis and tumor metastasis. Invasion Metastasis 14(1-6), 395-408 (1994).
55. Siracusano S, Vita F, Abbate R et al.: The role of granulocytes following intravesical BCG prophylaxis. Eur. Urol. 51(6), 1589-1597 (2007).
56. Bohle A, Thanhauser A, Ulmer AJ, Ernst M, Flad HD, Jocham D: Dissecting the immunobiological effects of bacillus Calmette-Guerin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon. J. Urol. 150(6), 1932-1937 (1993).
57. Jackson AM, Hawkyard SJ, Prescott S, Ritchie AW, James K, Chisholm GD: An investigation of factors influencing the in vitro induction of LAK activity against a variety of human bladder cancer cell lines. J. Urol. 147(1), 207-211 (1992).
58. Brandau S, Suttmann H, Riemensberger J et al.: Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette- Guerin-activated killer cells. Clin. Cancer Res. 6(9), 3729-3738 (2000).
59. Alexandroff AB, Jackson AM, Paterson T et al.: Role for CD40-CD40 ligand interactions in the immune response to solid tumours. Mol. Immunol. 37(9), 515-526 (2000).
60. Jackson AM, Alexandrov AB, Prescott S, James K, Chisholm GD: Role of adhesion molecules in lymphokine-activated killer cell killing of bladder cancer cells: further evidence for a third ligand for leucocyte function-associated antigen-1. Immunology 76(2), 286-291 (1992).
61. Suttmann H, Jocham D, Bohle A, Brandau S: The role of LFA-1 in the lysis of bladder cancer cells by bacillus Calmette-Guerin and interleukin 2-activated killer cells. Urol. Res. 30(4), 233-239 (2002).
62. Brandau S, Bohle A: Activation of natural killer cells by bacillus Calmette-Guerin. Eur. Urol. 39(5), 518-524 (2001).
63. Suttmann H, Jacobsen M, Reiss K, Jocham D, Bohle A, Brandau S: Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation. J. Urol. 172(4 Pt 1), 1490-1495 (2004).
64. Durek C, Brandau S, Ulmer AJ, Flad HD, Jocham D, Bohle A: Bacillus-Calmette- Guerin (BCG) and 3D tumors: an in vitro model for the study of adhesion and invasion. J. Urol. 162(2), 600-605 (1999).
65. Brandau S, Riemensberger J, Jacobsen M et al.: NK cells are essential for effective BCG immunotherapy. Int. J. Cancer 92(5), 697-702 (2001).
66. Alexandroff AB, Black J, Bollina PR, James K: Differential production of g/d T cells in the urine of bladder cancer patients receiving bacillus Calmette-Guerin immunotherapy. Int. J. Oncol. 10, 387-393 (1997).
67. Gueguen M, Patard JJ, Gaugler B et al.: An antigen recognized by autologous CTLs on a human bladder carcinoma. J. Immunol. 160(12), 6188-6194 (1998).
68. Simons MP, Nauseef WM, Griffith TS: Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer. Immunol. Res. 39(1-3), 79-93 (2007).
69. Ludwig AT, Moore JM, Luo Y et al.: Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for bacillus Calmette-Guerin- induced antitumor activity. Cancer Res. 64(10), 3386-3390 (2004).
70. Zhang Y, Khoo HE, Esuvaranathan K: Effects of bacillus Calmette-Guerin and interferon-a-2B on human bladder cancer in vitro. Int. J. Cancer 71(5), 851-857 (1997).
71. Brandau S, Bohle A, Thanhauser A et al.: In vitro generation of bacillus Calmette- Guerin-activated killer cells. Clin. Infect. Dis. 31(Suppl. 3), S94-S100 (2000).
72. Jackson AM, Alexandrov AB, Prescott S, James K, Chisholm GD: Expression of adhesion molecules by bladder cancer cells: modulation by interferon-g and tumour necrosis factor-α. J. Urol. 148(5), 1583-1586 (1992).
73. Jackson AM, Prescott S, Hawkyard SJ, James K, Chisholm G: The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical evans BCG therapy. Cancer Immunol. Immunother. 36(1), 25-30 (1993).
74. Hawkyard SJ, Jackson AM, Prescott S, James K, Chisholm GD: The effect of recombinant cytokines on bladder cancer cells in vitro. J. Urol. 150(2 Pt 1), 514-518 (1993).
75. Alexandroff AB, Robins RA, Murray A, James K: Tumour immunology: false hopes - new horizons? Immunol. Today 19(6), 247-250 (1998).
76. Cooke PW, James ND, Ganesan R, Wallace M, Burton A, Young LS: CD40 expression in bladder cancer. J. Pathol. 188(1), 38-43 (1999).
77. ODonnell MA, Luo Y, Chen X, Szilvasi A, Hunter SE, Clinton SK: Role of IL-12 in the induction and potentiation of IFN-g in response to bacillus Calmette-Guerin. J. Immunol. 163(8), 4246-4252 (1999).
78. Luo Y, Chen X, Downs TM, DeWolf WC, ODonnell MA: IFN-a 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy. J. Immunol. 162(4), 2399-2405 (1999).
79. Martin-Orozco N, Muranski P, Chung Y et al.: T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31(5), 787-798 (2009).
80. Murugaiyan G, Saha B: Protumor vs antitumor functions of IL-17. J. Immunol. 183(7), 4169-4175 (2009).
81. Wilson NJ, Boniface K, Chan JR et al.: Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 8(9), 950-957 (2007).
82. Boniface K, Blom B, Liu YJ, de Waal MR: From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol. Rev. 226, 132-146 (2008).
83. Alexandroff AB, Novitskaya ES, Armstrong DJ: Psoriasis as a multisystem inflammatory disease. In: Columbus F (Ed.). Advances in Medicine and Biology. Nova Science (2010) (In Press).
84. Oppmann B, Lesley R, Blom B et al.: Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13(5), 715-725 (2000).
85. Alexandroff AB, Pauriah M, Camp RD, Lang CC, Struthers AD, Armstrong DJ: More than skin deep -atherosclerosis as a systemic manifestation of psoriasis. Br. J. Dermatol. 161, 1-7 (2009).
86. Fietta P , Delsante G: The effector T helper cell triade. Riv. Biol. 102(1), 61-74 (2009).
87. Louten J, Boniface K, de Waal MR: Development and function of TH17 cells in health and disease. J. Allergy Clin. Immunol. 123(5), 1004-1011 (2009).
88. Zhu X, Mulcahy LA, Mohammed RA et al.: IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res. 10(6), R95 (2008).
89. Saban MR, Simpson C, Davis C et al.: Discriminators of mouse bladder response to intravesical bacillus Calmette-Guerin (BCG). BMC Immunol. 8, 6 (2007).
90. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H: IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 206(7), 1457-1464 (2009).
91. Banham AH, Powrie FM, Suri-Payer E: Foxp3+ regulatory T cells: current controversies and future perspectives. Eur. J. Immunol. 36(11), 2832-2836 (2006).
92. Tang Q , Bluestone JA: The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat. Immunol. 9(3), 239-244 (2008).
93. Coombes JL, Siddiqui KR, Rancibia-Carcamo CV et al.: A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-β and retinoic acid-dependent mechanism. J. Exp. Med. 204(8), 1757-1764 (2007).
94. Khader SA, Cooper AM: IL-23 and IL-17 in tuberculosis. Cytokine 41(2), 79-83 (2008).
95. Bettelli E, Carrier Y, Gao W et al.: Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 441(7090), 235-238 (2006).
96. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B: TGFb in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24(2), 179-189 (2006).
97. Ayyoub M, Deknuydt F, Raimbaud I et al.: Human memory Foxp3+ Tregs secrete IL-17 ex vivo and constitutively express the T(h)17 lineage-specific transcription factor RORg t. Proc. Natl Acad. Sci. USA 106(21), 8635-8640 (2009).
98. Voo KS, Wang YH, Santori FR et al.: Identification of IL-17-producing Foxp3+ regulatory T cells in humans. Proc. Natl Acad. Sci. USA 106(12), 4793-4798 (2009).
99. Lee SJ, Drabik K, Van Wagoner NJ et al.: ICAM-1-induced expression of proinflammatory cytokines in astrocytes: involvement of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways. J. Immunol. 165(8), 4658-4666 (2000).
100. Jackson AM, Alexandrov AB, Gribben SC, Esuvarnathan K, James K: Expression and shedding of ICAM-1 in bladder cancer and its immunotherapy. Int. J. Cancer 55(6), 921-925 (1993).
101. Young DG, Jackson AM, James K: Purification and characterisation of soluble intercellular adhesion molecule-1 and its effect on cell-mediated cytolysis of bladder tumour cells. Biochem. Soc. Trans. 25(2), 365S (1997). (Pubitemid 27261125)
102. Alexandroff AB, Graham-Brown RAC: Report from the 67th Annual Meeting of American Academy of Dermatology. Br. J. Dermatol. 162(1), 12-21 (2010).
103. Buijtels PC, Willemse-Erix HF, Petit PL et al.: Rapid identification of mycobacteria by Raman spectroscopy. J. Clin. Microbiol. 46(3), 961-965 (2008).
104. Kreunin P, Zhao J, Rosser C, Urquidi V, Lubman DM, Goodison S: Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J. Proteome Res. 6(7), 2631-2639 (2007).
105. Ahirwar DK, Agrahari A, Mandhani A, Mittal RD: Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy. Biomarkers 14(4), 213-218 (2009).
106. Ahirwar DK, Mandhani A, Dharaskar A, Kesarwani P, Mittal RD: Association of tumour necrosis factor-α gene (T-1031C, C-863A, and C-857T) polymorphisms with bladder cancer susceptibility and outcome after bacille Calmette-Guerin immunotherapy. BJU Int. 104(6), 867-873 (2009).
107. Haley JL, Young DG, Alexandroff A, James K, Jackson AM: Enhancing the immunotherapeutic potential of mycobacteria by transfection with tumour necrosis factor-α. Immunology 96(1), 114-121 (1999).
108. Young SL, Murphy M, Zhu XW et al.: Cytokine-modified Mycobacterium smegmatis as a novel anticancer immunotherapy. Int. J. Cancer 112(4), 653-660 (2004).
109. Heidecker L, Brasseur F, Probst-Kepper M, Gueguen M, Boon T, Van den Eynde BJ: Cytolytic T lymphocytes raised against a human bladder carcinoma recognize an antigen encoded by gene MAGE-A12. J. Immunol. 164(11), 6041-6045 (2000).